Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
American Journal of Physiology. Heart and Circulatory Physiology|July 19, 2002
Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytesYanlin Wang, Gilles W De Keulenaer, Ellen O Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assaysBegoña Comin-Anduix, Antonio Gualberto, John A Glaspy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2008
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myelomaMartha Q Lacy, Melissa Alsina, Rafael Fonseca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871Bruce D Cohen, Deborah A Baker, Catherine Soderstrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcomaHeribert Juergens, Najat C Daw, Birgit Geoerger, et al.
Molecular Cancer Therapeutics|July 31, 2020
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell CarcinomasMara Gilardi, Zhiyong Wang, Marco Proietto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptorJohann S de Bono, Gerhardt Attard, Alex Adjei, et al.
Scientific Reports|April 23, 2020
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphomaRuth Alonso-Alonso, Rufino Mondéjar, Nerea Martínez, et al.
Pageof 3